ESR2 and Familial prostate cancer: MCAM, ERα, and Erβ combined biomarker for the early detection of prostate cancer, a combination marker panel of MCAM, ERα, and ERβ increased the sensitivity to 75% and the specificity became 70% for the minimally invasive early detection test of PC with a sensitivity and specificity almost equal and better than serum PSA